2020 LUNG CANCER VOICES SUMMIT

JUNE 15-16, 2020

VIRTUAL
During this unprecedented COVID-19 pandemic, we transformed our annual National Advocacy Summit into a live virtual event, with a record number of lung cancer survivors, patients, caregivers, and advocates. Our united “go-to” force for advocacy and action brought together lung cancer warriors from across the country to educate Congress on the critical needs of our community, including additional research funding, early detection initiatives, and increased access to high-quality, affordable care.

The Virtual Voices Summit provided an opportunity for attendees to learn, train, and advocate—all from the safety of their own homes.

About the Virtual Lung Cancer Voices Summit

Bonnie J. Addario
Co-Founder, Board Chair

Laurie Fenton Ambrose
Co-Founder, President & CEO
The Numbers

- 236 Phone meetings with Senate and Representative offices
- 230 Lung cancer advocates including 163 survivors
- 28 Networking sessions
- 39 States represented
- 554 Messages exchanged by participants on Voices Summit virtual platform
- 50,000+ Impressions from #VoicesSummit and #FundOurLungs
- 4,000+ Social media engagements from event hashtags
Learn

Day 1 of the Voices Summit opened on June 15 with a warm welcome from Laurie Fenton Ambrose, Co-Founder, President, and CEO, followed by a Patient Keynote Address from Bonnie Addario, Co-Founder and Board Chair. During the subsequent Lung Cancer Living Room: The State of Lung Cancer Today and Impact Amid COVID-19, we welcomed:

- **William R. Mayfield, MD**, Thoracic Surgeon, Chief Surgical Officer, WellStar Health System; Vice Chair, GO2 Foundation for Lung Cancer Scientific Leadership Board
- **Jacob Sands, MD**, Physician, Dana-Farber Cancer Institute, Instructor of Medicine, Harvard Medical School; Board Member, GO2 Foundation for Lung Cancer Scientific Leadership Board
- And, our moderator: **Danielle Hicks**, Chief Patient Officer, GO2 Foundation for Lung Cancer

Throughout Day 1, attendees were able to connect with fellow survivors, caregivers, and advocates through virtual networking sessions.
Train

Day 2 started with guidance from Elridge Proctor, GO2 Foundation for Lung Cancer’s Senior Director of Government Affairs and Public Policy. She led a training session for advocates on how to make your voice heard.

Attendees received strategies and tips for telling their personal stories to congressional representatives, including ways to urge lawmakers to support the Lung Cancer Research Program housed in the Department of Defense Congressionally Directed Medical Research Programs (CDMRP), a dedicated pipeline funding vital research into the early detection and treatment of lung cancer.

1 https://go2foundation.org/advocacy/our-legislative-priorities/department-of-defense-research-funding/
Virtual Congressional Meetings

Though meetings didn’t take place on Capitol Hill, the congressional phone calls were full of compelling advocate stories followed by forceful requests that Members of Congress support new treatments and future cures through increased research funding.

Our powerful advocates requested that the Lung Cancer Research Program (LCRP), funded at $20 million in Fiscal Year 2009 (FY09) be funded at that level in FY21 through the Congressionally Directed Medical Research Programs (CDMRP) at the Department of Defense (DoD). These voices were heard.
**Awareness**  Using the Advocacy Action Toolkit, advocates across the country raised awareness via social media by sharing lung cancer facts and calling for increased research.
PROGRAM DESCRIPTION

DISEASE(S) UNDER INVESTIGATION

PHASE 1 PHASE 2 PHASE 3

BRENTUXIMAB VEDOTIN 1
  CD30 Antibody Drug Conjugate
  Hodgkin Lymphoma, Cutaneous T-Cell Lymphoma, Mature T-Cell Lymphoma, Anaplastic Large Cell Lymphoma

BRIGATINIB
  ALK Inhibitor
  Non-small Cell Lung Cancer

IXAZOMIB
  Proteasome Inhibitor
  Multiple Myeloma, Amyloidosis

LEUPRORELIN ACETATE 2
  LH-RH Agonist
  Prostate Cancer, Breast Cancer, new formulation

PANITUMUMAB 3
  Anti-EGFR Antibody
  Colorectal Cancer

PEVONEDISTAT
  Nedd8-Activating Enzyme Inhibitor
  High-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Low-Blast Acute Myelogenous Leukemia, Solid Tumors

PONATINIB 4
  BCR-ABL Inhibitor
  Chronic Myeloid Leukemia
  Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

SAPANISERTIB (TAK-228)
  TORC1/TORC2 Inhibitor
  Breast Cancer, Renal Cell Carcinoma, Endometrial Cancer

TAK-117
  PI3K Alpha Inhibitor
  Renal Cell Carcinoma

TAK-659
  SYK/FLT-3 Inhibitor
  Lymphoma, Acute Myelogenous Leukemia, Solid Tumors

TAK-931
  CDC7 Inhibitor
  Pancreatic Cancer, Colorectal Cancer

VEDOLIZUMAB
  Anti-α4β7 Antibody
  Graft versus Host Disease

TAK-243
  Ubiquitin-Activating Enzyme Inhibitor
  Solid Tumors

TAK-522 (XMT-1522)
  HER2 Dolaflexin Antibody Drug Conjugate
  Breast Cancer

TAK-573
  CD38-targeted IgG4 fused with attenuated IFNα
  Multiple Myeloma

TAK-580
  Pan-Raf Inhibitor
  Solid Tumors

TAK-788 (AP32788)
  EGFR/HER2 Inhibitor
  Non-small Cell Lung Cancer

CABOZANTINIB 2
  MET, VEGF, AXL and RET Inhibitor
  Renal Cell Carcinoma Development in Preparation

NIRAPARIB 6
  PARP Inhibitor
  Solid Tumors Development in Preparation

All programs have Global Development Rights unless otherwise noted.

1 Brentuximab vedotin is co-developed by Takeda and Seattle Genetics, Inc.
2 Japan Only.
3 Japan Only. In-Licensed.
4 Takeda shares development rights with Incyte (Europe, Turkey and Israel) and Otsuka (Asia Pacific territories).
5 Ex-Us, Ex-Canada. TAK-522 (XMT-1522) is co-developed by Takeda and Mersana Therapeutics, Inc.
6 Niraparib is being developed under a licensing agreement with Tesaro, Inc. for all tumor types in Japan and all tumor types excluding prostate cancer in South Korea, Taiwan, Russia and Australia.

Last updated 2017-10-31